Levetiracetam: a Practical Option for Seizure Management in Elderly Patients with Cognitive Impairment

Overview

Journal Am J Alzheimers Dis Other Demen

Publisher Sage Publications

Specialty Neurology

Date 2008 Nov 13

PMID 19001351

Citations 17

Authors

Carol F Lippa

Andrea Rosso

Marjorie Hepler

Sigmund Jenssen

Jyoti Pillai

David Irwin

Affiliations

Soon will be listed here.

Abstract

Cognitive impairment and seizures are common in our aging population. Anticonvulsant treatment is problematic due to sedation, cognitive slowing, and behavioral changes. Levetiracetam has favorable pharmacokinetics, good efficacy in elderly individuals, a favorable side effect profile, and lacks major drug interactions. We conducted a prospective, uncontrolled, phase 4, open label, 12-week study of levetiracetam to better profile its efficacy, safety, and impact on cognitive/behavioral status in 24 cognitively impaired, elderly individuals. In total, 69% were seizure free for the duration of the study; the remaining participants had satisfactory seizure control. Fatigue was the most common side effect (5 participants). Significant overall improvements were observed for the Folstein's Mini-Mental State Examination and the Alzheimer's Disease Assessment Scale-Cognitive. No significant changes were seen in behavioral or functional measures. Levetiracetam is an effective antiepileptic drug in elderly individuals with cognitive impairment. At 3 months, participants who remained on levetiracetam showed excellent cognitive tolerability.

Citing Articles

Impact of levetiracetam on direct oral anticoagulant level and outcomes among older Asian patients with atrial fibrillation.

Huang Y, Chen T, Huang Y, Kuo C, Peng Y, Tang S Front Pharmacol. 2025; 16:1505665.

PMID: 40046754 PMC: 11880207. DOI: 10.3389/fphar.2025.1505665.

The Role of Epileptic Activity in Alzheimer's Disease.

Chen T, Lai M, Hong W, Huang C Am J Alzheimers Dis Other Demen. 2024; 39:15333175241303569.

PMID: 39576820 PMC: 11585063. DOI: 10.1177/15333175241303569.

Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trial.

Sen A, Toniolo S, Tai X, Akinola M, Symmonds M, Mura S Epilepsia Open. 2024; 9(6):2353-2364.

PMID: 39400461 PMC: 11633694. DOI: 10.1002/epi4.13070.

Assessing the Incidence Rate of Neuropsychiatric Adverse Effects in Older Adults Following Levetiracetam Initiation: A Retrospective Study.

Basheikh M Int J Gen Med. 2024; 17:2011-2020.

PMID: 38736674 PMC: 11088830. DOI: 10.2147/IJGM.S458803.

Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's disease.

Burton C, Chumin E, Collins A, Persohn S, Onos K, Pandey R Front Neurosci. 2024; 17:1336026.

PMID: 38328556 PMC: 10847229. DOI: 10.3389/fnins.2023.1336026.

References

Tariot P, Mack J, PATTERSON M, Edland S, Weiner M, Fillenbaum G . The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995; 152(9):1349-57. DOI: 10.1176/ajp.152.9.1349. View

Ritchie K, Touchon J . Mild cognitive impairment: conceptual basis and current nosological status. Lancet. 2000; 355(9199):225-8. DOI: 10.1016/S0140-6736(99)06155-3. View

Sirven J, Ozuna J . Diagnosing epilepsy in older adults: what does it mean for the primary care physician?. Geriatrics. 2005; 60(10):30-5. View

Briggs D, French J . Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf. 2004; 3(5):415-24. DOI: 10.1517/14740338.3.5.415. View

Ebly E, Hogan D, Parhad I . Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol. 1995; 52(6):612-9. DOI: 10.1001/archneur.1995.00540300086018. View

French J, Edrich P, Cramer J . A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res. 2001; 47(1-2):77-90. DOI: 10.1016/s0920-1211(01)00296-0. View

Cramer J, Leppik I, De Rue K, Edrich P, Kramer G . Tolerability of levetiracetam in elderly patients with CNS disorders. Epilepsy Res. 2003; 56(2-3):135-45. DOI: 10.1016/j.eplepsyres.2003.08.010. View

Petersen R, Doody R, Kurz A, Mohs R, Morris J, Rabins P . Current concepts in mild cognitive impairment. Arch Neurol. 2001; 58(12):1985-92. DOI: 10.1001/archneur.58.12.1985. View

Mendez M, Lim G . Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003; 20(11):791-803. DOI: 10.2165/00002512-200320110-00001. View

10.

Patsalos P . Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004; 43(11):707-24. DOI: 10.2165/00003088-200443110-00002. View

11.

Arroyo S, Crawford P . Safety profile of levetiracetam. Epileptic Disord. 2003; 5 Suppl 1:S57-63. View

12.

Folstein M, Folstein S, McHugh P . "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3):189-98. DOI: 10.1016/0022-3956(75)90026-6. View

13.

Piazzini A, Chifari R, Canevini M, Turner K, Fontana S, Canger R . Levetiracetam: an improvement of attention and of oral fluency in patients with partial epilepsy. Epilepsy Res. 2005; 68(3):181-8. DOI: 10.1016/j.eplepsyres.2005.10.006. View

14.

Grundman M, Petersen R, Ferris S, Thomas R, Aisen P, Bennett D . Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004; 61(1):59-66. DOI: 10.1001/archneur.61.1.59. View

15.

Patsalos P . The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol. 2003; 25(2):123-9. DOI: 10.1358/mf.2003.25.2.723686. View

16.

Hebert L, Scherr P, Bienias J, Bennett D, Evans D . Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60(8):1119-22. DOI: 10.1001/archneur.60.8.1119. View

17.

Burch Jr E, Andrews S . Comparison of two cognitive rating scales in medically ill patients. Int J Psychiatry Med. 1987; 17(2):193-200. DOI: 10.2190/gcvn-d2lj-aph3-kn0k. View

18.

Jacobson M . Epilepsy in Aging Populations. Curr Treat Options Neurol. 2001; 4(1):19-30. DOI: 10.1007/s11940-002-0002-8. View

19.

McRae C, Diem G, Vo A, OBrien C, Seeberger L . Schwab & England: standardization of administration. Mov Disord. 2000; 15(2):335-6. DOI: 10.1002/1531-8257(200003)15:2<335::aid-mds1022>3.0.co;2-v. View

20.

Belcastro V, Costa C, Galletti F, Pisani F, Calabresi P, Parnetti L . Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol. 2007; 14(10):1176-8. DOI: 10.1111/j.1468-1331.2007.01907.x. View